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ABSTRACT
Head and Neck cancer (HNC) is a complex mix of cancers and one of the more 
common cancers with a relatively poor prognosis. One of the factors that may assist us 
in predicting survival and allow us to adjust our treatment strategies is the presence 
of tumor hypoxia. In this overview we aim to evaluate the current evidence and 
potential clinical relevance of tumor hypoxia in head and neck cancer according to 
an extensive search of current literature. 
An abundance of evidence and often contradictory evidence is found in the 
literature. Contradictions and comparisons are difficult to judge as criteria and 
methodologies differ greatly, furthermore few prospective observational studies 
exist for verification in pre-clinical studies. Despite these discrepancies there is clear 
evidence of associations between prognosis and poor tumor oxygenation biomarkers 
such as HIF-1α, GLUT-1 and lactate, though these associations are not exclusive. The 
use of genetic markers is expanding and will probably lead to significantly more and 
complex evidence. The lack of oxygenation in head and neck tumors is of paramount 
importance for the prediction of treatment outcomes and prognosis. Despite the wide 
array of conflicting evidence, the drive towards non-invasive prediction of tumor 
hypoxia should continue.
INTRODUCTION
Head and neck cancer (HNC) constitutes 5.1% (> 
633 000) of all new cancers and relates to 4.8% of all 
cancer deaths annually worldwide with Head and Neck 
Squamous Cell Carcinomas (HNSCC) contributing by 
far the largest number [1]. Major risk factors are smoking 
(smokers are ten times more likely to develop HNSCC 
than non-smokers), alcohol abuse and HPV infection [2]. 
The main sites for HNSCC are the larynx, pharynx and 
oral cavity [1]. HNSCC is common only in its general 
anatomic localization as it is a diverse disease with 
regards to etiology, presentation, response to treatment and 
prognosis. Despite this diversity, there are some common 
features that may lead to local and regional recurrence and 
predict disease-specific survival. One of these features is 
the presence of hypoxia in the tumor [3]. 
Since hypoxic tumors show a poorer response 
to surgery and radiotherapy than non-hypoxic tumors, 
prior therapy knowledge on the presence and extent of 
the hypoxia is needed [4, 5]. Currently, except for in-
dwelling catheters, adequate information regarding the 
extent of the tumor hypoxia can only be gathered after 
tumor resection and histological processing. A wide array 
of tumor hypoxia biomarkers has been identified, however, 
to our knowledge no pre-excision predictive parameters 
are available. Except for the radio-oncology field where 
hypoxia predictive markers are now being implemented in 
some clinics, evidence is lacking regarding modifications 
that may be undertaken to optimize treatment [6-8]. 
The goal of this paper is to demonstrate the 
complexity, summarise and discuss the current literature 
evidence and potential clinical relevance of tumor hypoxia 
and its biomarkers in HNC. A PubMed and Medline 
search was performed using the keywords tumor hypoxia, 
pimonidazole, biomarkers, HIF-1alpha, CA-IX, Nitric 
oxide, smoking, anemia, VEGF, lactate, miRNA, head and 
neck cancer, and head and neck squamous cell carcinoma 
either alone or in combination. Articles were screened 
according to their level of clinical and scientific evidence 
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as well as clinical relevance to the topic.
WHAT IS TUMOR HYPOXIA?
Tumor hypoxia can be defined as a low oxygen 
tension (pO2) in the tumor compared to the surrounding 
tissue of pO2 ≤ 2.5 mmHg, but is most commonly 
defined as a pO2 ≤ 10 mmHg [9]. A functional definition 
may be more appropriate in such an individualized and 
complex environment and therefore, at our current level 
of knowledge, tumor hypoxia starts when Hypoxia-
inducible Factors (HIF)-subunits become stabilized due to 
limited oxygen availability compared to oxygen demand. 
More than 50% of solid tumors display heterogenous 
hypoxic areas irrespective of their size and histological 
characteristics [10-12]. Oxygen content within tissues is 
dependent on a number of complex factors such as the 
physical presence of oxygen, the programming of tumor 
and stroma cells whether to utilize the available oxygen, 
vasculature, perfusion and diffusion distance that may 
be influenced by vascular density and edema, as well as 
systemic factors such as anemia or chronic obstructive 
lung disease.
GENERAL CONDITIONS INFLUENCING 
TUMOR HYPOXIA 
Role of vasculature/microcirculation in tumor 
hypoxia
The vasculature in tumors originate from host 
vessels and neovascularisation due to tumor angiogenesis 
factors [13]. If the incorporated vasculature is insufficient 
for the tumor mass, reduction in oxygen exchange will 
develop. This hypoxic state will stimulate reperfusion via 
neovascularisation in an attempt to restore the blood flow 
and improve the oxygen supply via a variety of metabolic 
pathways of which the HIF-1 alpha pathway is central 
[14, 15]. This state of poor vascularity in terms of density, 
quality of blood flow, increased diffusion distance and 
permeability may also implicate poorer drug delivery and 
treatment response [16, 17]. 
The neovascularisation induced vessels are often 
tortuous and haphazard resulting in a sluggish perfusion, 
increased vessel permeability and distance from intact 
blood vessels [3, 18] (Figure 1). Therefore, a highly 
Figure 1: Tumor showing hypoxic cells beyond the oxygen diffusion limit of 70 µm and close to newly formed tortuous, 
haphazard blood vessels that have sluggish perfusion. Functional venous drainage, preventing edema is also important, but not 
demonstrated here.
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vascularised tumor is not necessarily indicative of a highly 
oxygenated tumor [13]. This vascular-dependent relative 
hypoxic state does not necessarily lead to an anaerobic 
metabolic state of the tumor cells (Warburg effect). 
Two subtypes of hypoxia have been described. 
Acute hypoxia is defined as a local disturbance in 
perfusion. The disturbance can be caused by the loss of 
microvascular blood flow or by strong variations in red 
blood cell fluxes which results in decreased microvascular 
oxygen supply to the tumor area due to the tortuous and 
aberrant vasculature and may be a transient phenomenon 
[19, 20]. Upon revascularization with well-oxygenated 
blood, free oxygen radicals are released causing further 
tissue damage and even necrosis. When tumor growth is 
greater than neo-vascularisation, perivascular necrosis 
develops at a distance of 130-150µm from nutrient vessels 
and cells further away than 70 µm from the vessels already 
show hypoxic tension indicating the oxygen diffusion 
limit (Figure 1). This phenomenon is called chronic 
or diffusion-limited hypoxia and can activate stress-
response genes and is typical of a re-vascularisation or 
re-oxygenation injury, explaining central necrosis, often 
found in fast growing tumors. This central necrosis is at 
least partially the cumulative end result of both acute and 
chronic hypoxia in the tumor microenvironment [21]. 
Especially in initial stages, cancer cells may also need 
other growth factors, and they will be selected by necrosis 
until they gain a mutation that renders them growth factor 
independent. Generating a universal definition of hypoxia 
may thus be difficult and probably needs to sub-defined 
depending on the particular measurement assay which may 
be physical or a genetically or local environment dictated 
metabolic measurement. Important also is to consider non-
inherent tumor factors, like anemia, smoking, decreased 
lung function or post radiation related poor perfusion 
in HNC patients that may influence tumor hypoxia. 
Decreased blood flow has a negative effect on the oxygen 
delivery to a tumor area and this is often termed hypoxia, 
but strictly defined, the term ischemia should be used for 
this phenomenon. Hypoxemia is defined as less oxygen in 
the blood due to decreased hemoglobin-oxygen saturation. 
Anemia and tumor hypoxia
Anemia plays a role in tumor hypoxia [13]; it 
is defined as a hemoglobin (Hb) level less than 12.0 g/
dl in females and less than 13.8 g/dl in males, and has 
long been known as a prognostic factor in HNC [3]. Post-
operative acute anemia (Hb<12 g/dl) has been described as 
an independent prognostic factor for local recurrence-free 
survival [5, 22, 23]. Nordsmark et al. [24] and Nordsmark 
[25] found a correlation between median pO2 levels (9 
mmHg; range 0-62 mmHg) and Hb levels but when they 
subcategorized into pO2<2.5 mmHg and pO2<5 mmHg, 
they found no correlation between pO2 and Hb. 
Pre-operative anemia plays a significant role in 
overall survival [23]. Low Hb levels may impair survival 
by impairing tissue and possibly tumor oxygenation 
causing hypoxia and thereby reducing the effectiveness of 
chemotherapy and radiotherapy [26, 27]. Compounding 
the complexity of the matter is evidence that blood 
transfusion may lead to a worse prognosis [28]. Bhide et 
al. [29] and Hoff et al. [30] found that blood transfusion 
before and during radiotherapy in HNC patients had no 
effect on survival and may in fact be deleterious. This 
paradox may be explained by the leakage of endothelial 
growth factors from the aging red blood cells that may 
encourage tumor growth and have a deleterious effect 
on immune regulation. This evidence should encourage 
us to move away from the common notion of transfusing 
patients with an Hb < 10 g/dl or a hematocrit (Hct) < 30%. 
Vaupel et al [31] found that an Hb level between 12 and 
14 g/dl was optimal for tumor oxygenation even though 
no correlation has been found between Hb level and pO2 
[32, 33]. 
Erythropoietin (EPO) is a glycoprotein that 
regulates erythrocyte production by stimulating growth, 
preventing apoptosis and inducing differentiation of 
red blood cell precursors. Increasing the Hb levels with 
EPO has led to contradictory results. Henke et al. [34] 
showed a decrease in recurrence in pelvic malignancies 
in patients administered erythropoietin alfa and iron 
compared to patients who received iron only. It was later 
shown that EPO treatment during radiotherapy may have 
a detrimental effect on loco-regional progression-free 
survival and overall survival in HNC patients despite an 
increased Hb [35]. This negative effect of EPO could be 
due to the fact that the Hb levels were increased to around 
14.8 g/dl which falls outside the beneficial range (12 g/dl 
to 14 g/dl) suggested by Vaupel et al [31]. This argument 
is controversial because in the experiments performed by 
Glaser et al [36], two groups had a starting Hb level > 
14.5 g/dl and these patients had a good overall response 
to neo-adjuvant chemotherapy. Neither Henke et al. [35] 
nor Glaser et al. [36] investigated the effects of EPO 
administration on tumor hypoxia. In vivo, EPO appears to 
have no effect on tumor growth or radiotherapy efficacy 
[37, 38]. Furthermore, no correlation has been found 
between Hb and tumor hypoxia markers such as HIF-
1alpha, HIF-2alpha, and Carbonic Anhydrase-IX (CA-IX) 
[39, 40], however in a cervical cancer cohort anemia did 
correlate with HIF-1alpha expression [27]. 
Total Hb levels cannot be used to indirectly 
determine oxygen delivery to tissue as it does not take 
into account blood flow, Hb saturation, oxygen-Hb 
dissociation, or the quality of the Hb [41]. 
Although no overwhelming evidence, anemia 
has been shown to interrelate anemia and tumor 
hypoxia, anemia remains an important factor in patient 
survival. There is, however, evidence that implicates 
carboxyhemoglobin in tumor hypoxia. 
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Smoking and tumor hypoxia
Smoking is one of the main risk factors for HNSCC 
and the main source of carbon monoxide (CO). Patients 
who continue smoking during radiation have a worse 
prognosis than non-smokers [42, 43]. Carboxyhemoglobin 
is defined as Hb-bound CO [44]. Hb has an approximately 
200-280 fold higher affinity for CO than for oxygen, 
therefore low amounts of CO will impact on the oxygen-
hemoglobin dissociation curve by shifting it left, resulting 
in diminished tumor blood perfusion as well as the 
amount of oxygen bound to Hb [44]. Increased HbCO 
in HNC patients who smoke, results in a decreased 
oxygen unloading capacity [41]. This means that most of 
the oxygen that enters a tumor subsequently leaves the 
tumor in venous blood outflow. A rise of HbCo to 12 % 
(compared to the average of 4.6% in smokers) results in a 
25 % reduction in oxygen available to the tumor [41]. CO 
causes a 50 % reduction in blood flow to tumors and a 50 
% increase in tumor hypoxia in mice [45]. 
Cigarette smoke also contains nicotine which 
impairs wound healing by vasoconstriction thus 
decreasing blood flow to the wound [46]. Nicotine and its 
derivatives play a role in tumor progression and metastasis 
by increasing oxidative stress and activating NF-kappaB 
and other proliferation signaling pathways [47]. Nicotine 
promotes proliferation of nasopharyngeal carcinoma cells 
by inducing HIF-1alpha and vascular endothelial growth 
factor (VEGF) and inhibiting pigment epithelium-derived 
factor (PEDF), a known anti-angiogenic, anti-tumorigenic 
protein [48]. 
Alcohol and tumor hypoxia
Alcohol and more so, alcohol and smoking 
combined, are major risk factors for HNSCC (Figure 2) as 
alcohol may act as a solvent for cigarette smoke. Although 
no direct correlations have been made between alcohol 
and tumor hypoxia, alcohol increases HIF-1alpha via 
oxidative stress in a rat model for alcoholic liver disease 
[49]. Alcohol is metabolized to acetaldehyde, a known 
carcinogen, by alcohol dehydrogenase (ADH) situated in 
the liver, gastric mucosa, oesophageal mucosa and oral 
mucosa [50]. Most of the harmful effects of alcohol are 
mediated via acetaldehyde through DNA damage, but 
alcohol can increase mucosal permeability and cause 
changes in mucosal morphology [50]. The relationship 
between alcohol consumption and tumor hypoxia in HNC 
has not been investigated thus far. However, baboons 
fed alcohol chronically showed decreased oxygen 
consumption in the liver accompanied by increased 
acetaldehyde concentrations and impaired mitochondrial 
function [51]. It is therefore possible that alcohol also 
plays a role in tumor hypoxia in HNSCC. Not all HNSCC 
patients drink alcohol and/or smoke tobacco which brings 
our focus to the human papillomavirus.
Human Papillomavirus (HPV) and tumor hypoxia
HPV causes up to 70 % of oropharyngeal cancers 
but less oral cancers. Contradicting results exist pertaining 
to the effect of HPV on HIF-1alpha. HPV-16 induces 
HIF-1alpha expression in vitro and ex vivo in head and 
Figure 2: Hypoxic pathway possibly relates to smoking, leading to increased tumor aggressivity and poorer prognosis 
in HNC.
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neck tumor specimens [52-54]. Hong et al. [55] however, 
found no relationship between HPV-status and HIF-1alpha 
expression in patients with oropharyngeal cancer but 
patients with the worst prognosis tended to be those who 
were HPV-negative and HIF-1alpha positive.
HPV-positive tumors grow faster and show 
aggressive regional metastasis, yet the patients have 
a better prognosis and a better response to radio- and 
chemotherapy [56]. Comparatively, tumor hypoxia 
has also been linked to increased metastasis, but has 
a worse prognosis and a worse response to radio- and 
chemotherapy. Rodolico et al. [54] concluded that the 
increase in HIF-1alpha in HPV-positive tumors was 
oxygen-independent since the HIF-1alpha immune 
reactivity also occurred close to blood vessels, however 
Janssen et al. [57] also found that this immunoreactivity 
did not correlate with the pimonidazole staining. Trinkaus 
et al. [58] could not find an association between p16-
positive patients with locally advanced head and neck 
tumors and hypoxic imaging using (18F)-misonidazole 
positron emission tomography, equally Mortensen et 
al. [59] could not demonstrate this by use of FAZA-
PET in the DAHANCA trial. One would expect a less 
pronounced hypoxia association as HPV-positive patients 
with oropharyngeal cancer mostly have a more favorable 
prognosis, however the role of HPV in tumor hypoxia still 
has to be fully explored. Comprehensive gene profiling 
of HNSCC has been performed, highlighting the different 
pathways of HPV and non HPV induced HNSCC, but not 
yet covering all hypoxia pathways [60].Comprehensive 
discussion of HPV and its relation to HNSCC is not within 
the scope of this paper.
HPV causes HNSCC in a different way with, non-
mutated p53 and producing E6 and E7 oncogenes with its 
own unique way to manipulate the immunological system. 
Clearly immunity is becoming a focal point of cancer 
research.
Immune system and tumor hypoxia
Inflammation appears to play a central role in the 
development of cancer and as far back as 1863, Virchow 
postulated that a process of chronic irritation or irritants 
may lead to injury and an inflammatory process that will 
enhance cell proliferation and development of cancer, 
including oral cancer [61, 62]. Cigarette smoke also 
affects the immune system by impairing immunity in the 
oral cavity and promoting gingival and periodontal disease 
and oral cancer [63]. Cigarette smoke contains bacterial 
lipopolysaccharides, reactive oxygen species and other 
reactive compounds that induce chronic inflammation in 
the oral mucosa and modify host responses to exogenous 
antigens [63]. Viral infections and especially HPV in 
HNSCC may play a role in immunosuppression by 
infecting pluripotent stem cells, resulting in oncogenic 
changes that are replicated in the background of a poorly 
responsive immune system [10, 62, 64]. The expressions 
of the viral oncogenes E6 and E7 are important in the 
process of changing stem cells because they lead to the 
inactivation of one of the immune defense mechanisms, 
the tumor suppressor genes p53 and pRb [65]. A biological 
explanation for the improved prognosis of HPV-positive 
versus HPV-negative cancer patients has not been 
established. Bose et al. [10] hypothesized that p53 and 
pRb remain intact in HPV-positive cases whereas they are 
mutated in HPV-negative cases. 
Multiple pathways for the initiation and later 
association and reactive changes of inflammation and 
tumor development have been described. Loss of cellular 
senescence and development of cancer stem cells may 
be propagated by stress factors like inflammation and 
hypoxia [66]. Chronic inflammation associated with 
poor oral hygiene and Lichen Planus (an autoimmune 
disease) and oral cancer has been shown in more than 
1% of afflicted patients [62]. In early premalignant 
lesions, inflammation-induced neovascularisation has 
been observed in the stromal component of verrucous 
hyperplasia and hyperkeratosis [67]. The composition of 
cytokine/chemokines, liberated from monocytes at a site of 
inflammation and which are important in the development 
of a chronic state of disease, can broadly be divided into 
pro-inflammatory and anti-inflammatory cytokines. One 
of these cytokines is tumor necrosis factor-α (TNF-α), a 
pro-inflammatory cytokine that has both a positive and 
negative effect on inflammation and has a controlling 
effect on pro-inflammatory cell populations. Interleukins 1 
and 6 are associated with tumor metastasis and interleukins 
8 and 12 have been associated with inflammation and 
cancer [61, 62].
The role of inflammation, hypoxia, lactate, glucose 
metabolism and angiogenesis in oncogenesis is highlighted 
by various associations like CXCL12 that may play a role 
in the immune response by activating CD8 and T cells 
in established HNSCC [62, 68]. CXCR4 and CXCL12, 
both also described as HIF targets, are highly expressed in 
HNSCC and correlate with poor prognostic outcome due 
to increased metastasis and increased resistance to therapy 
[69]. Glucose and its possible role in tumor hypoxia, along 
with diabetes is described later in this manuscript.
In a study by Dumitru et al. [70] an association 
between AHNAK/Desmoyokin, a giant protein associated 
with poorer immune defense and an increased migration 
inhibitory factor (MIF, also a HIF target), and increased 
level of neutrophil tumor infiltration was established in 
laryngeal cancer patients with poor prognosis. Factors 
released by neutrophils enhance tumor migration in a 
feedback manner [70]. The role of the inflammatory 
process and its controlling proteins and prescribing gene 
pool is intricate and new discoveries slowly enhance our 
understanding.
Up to now we have described the interplay between 
the tumor environment and tumor hypoxia. Pimonidazole, 
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an exogenous biomarker for tumor hypoxia, has thus far 
been the gold standard. Endogenous biomarkers such as 
LDH-5, HIF-1α, CA-IX, GLUT-1 and MCT4 may show 
some clinical relevance [57, 71-74].
ENDOGENOUS BIOMARKERS IN 
TUMOR HYPOXIA
It is important to recognize that most biopsy 
specimens are adequate for diagnosis of malignancy, 
but may not be a representative metabolic sample of the 
tumor. This is because: 1. Biopsy specimens are taken 
from variable, mostly peripheral parts of the tumor 
that may represent different states of perfusion [10]; 2. 
Tumors often show heterogenous metabolic activity and 
large tumors display areas of acute and chronic hypoxia 
that may not be represented by a single or even multiple 
biopsies [25]; 3. Tumor hypoxia is a dynamic process 
and tumors may display signs of hypoxia earlier or 
later in their development; and 4. Hypoxia is not a size-
dependent factor and shows a poor relationship with 
other clinicopathological factors like differentiation and 
lymph node metastasis. Despite the above, a significant 
relationship to prognosis exists, demonstrating poor 
sensitivity, specificity and a poor understanding and 
interrelationship of our current prognostic predictive 
methods [3, 75].
 Janssen et al. [3] raised interesting questions 
regarding the endogenous markers for hypoxia – i.e. is 
the marker only dependent on hypoxia for its expression 
or do other factors play a modulating role? Is the marker 
expressed (under hypoxia) in all tumor types? Is the 
marker expressed under acute and chronic hypoxia i.e. 
what is the time scale for upregulation after hypoxia 
induction? With these questions in mind, we discuss the 
more common biomarkers used for tumor hypoxia.
HIF and tumor hypoxia
HIF form a family of heterodimeric transcription 
factors that are upregulated in response to hypoxia and 
regulate hypoxia-driven changes in tumor cells. HIF-
1alpha is a member of this family and is often used as a 
marker for tumor hypoxia. The understanding thus far has 
been that in normoxic conditions, HIF-1alpha subunits are 
degraded whereas in hypoxia, the degradation is inhibited 
when the enzymes that modify HIF become inactive. 
HIF-1alpha then binds to hypoxia response elements and 
regulates changes in expression of VEGF, CA-IX, glucose 
transporter (GLUT-1), EPO, plasminogen activator 
inhibitor-1 (PAI-1) and others (Figure 3). In recent years 
it has been shown that HIF-1alpha expression is not only 
regulated by hypoxia but by nitric oxide [76-78], reactive 
oxygen species [78, 79], cytokines and growth factors 
such as TGF-beta [80, 81] and insulin [82], factors not 
necessarily associated with tumor hypoxia. HIF-1alpha 
is activated at physiological pO2 in a mitogen activated 
protein kinase (MAPK)-dependent manner and is needed 
Figure 3: Hypoxic related biomarkers that may play a role in the hypoxic pathway leading to increased tumor 
aggressivity.
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for proliferation various cancer cell lines and in normal 
human keratinocyte cells [83]. Janssen et al. [57] found no 
correlation between pimonidazole and HIF-1alpha staining 
and concluded that HIF-1alpha is not a suitable marker for 
chronic hypoxia. It would appear that HIF-1alpha is only 
transiently induced and then undergoes (partial) feedback 
inhibition [84]. Pimonidazole staining increased with 
distance from the blood vessels which corroborated the 
findings of Wijffels et al. [85]. Furthermore, Joshi et al. 
[86] recently found that hypoxia alone is not sufficient to 
stabilize HIF-1alpha and that HIF-1alpha can be degraded 
during hypoxia by the 26 S proteasome via the E3 ligase 
MDM2 [86]. 
Diabetes is recognized as a risk factor for oral 
cancer [87]. In an epidemiological study in Hungary, 24.3 
% of the patients who had malignant oral lesions also had 
impaired glucose metabolism [88]. A higher percentage 
of type 2 diabetic patients, who are characterized by 
increased circulating insulin due to insulin resistance, had 
malignant lesions compared to type 1 diabetic patients. 
Cholesterol and insulin (both of which are elevated in 
Type 2 diabetes) increase HIF-1alpha. Although the 
effects of HIF-1alpha, along with VEGF are not unique to 
hypoxia, they are of significant therapeutic interest. 
Vascular endothelial growth factor (VEGF) and 
tumor hypoxia
VEGF is a hypoxia-responsive gene and is a key 
player in the development of tumor vascularisation [89]. 
Increased VEGF production by tumor cells is associated 
with poor prognosis, nodal metastasis, clinical stage 
and low survival in HNSCC [90]. It is upregulated in 
decreasing concentrations of oxygen in vitro and in vivo 
[91-93] in HNSCC via Jun N terminal kinase (JNK-1) and 
p38 kinase which are stress activated protein kinases [94]. 
To further complicate matters, VEGF is also regulated by 
many other factors in normoxic conditions [95].
Kennedy and Frank [96] investigated human retinal 
epithelial cells and confirmed the findings of Katavetin et 
al. [97] who showed that high glucose levels diminished 
the effect of hypoxia on VEGF. Low glucose and hypoxia 
(i.e. low pO2) resulted in a significant increase in VEGF 
levels and the authors concluded that the cells used VEGF 
and angiogenesis as a compensatory mechanism when 
both fuel sources (oxygen and glucose) were depleted. 
As clearly shown in Figure 4, tumor cells need a high 
concentration of glucose, a fact exploited in FDG (F- 
Fluordesoxyglucose) PET scans.
Tumors will not grow larger than 1-2mm3 if 
neovascularisation, with the formation of an intra-tumor 
capillary network, does not take place. Neovascularisation 
Oncotarget8www.impactjournals.com/oncotarget
Figure 4: Oxidative phosphorylation in the presence of a) high levels of or b) low levels of oxygen, where glucose is 
metabolized to H20 and CO2 with the production of a) high ATP or b) low ATP in a normal cell. c) Proliferating or tumor 
cells produce low levels of ATP and convert glucose into lactate in the presence of oxygen. This is called aerobic glycolysis or the Warburg 
effect. It is postulated that tumor cells use the energy for proliferation and replication.
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seems mainly to be induced by VEGF but recently nitric 
oxide (NO) has also been implicated in this process [91, 
98]. Hypoxic head and neck tumors have a high glucose 
uptake and the pimonidazole staining for hypoxia shows 
that the cells are far from blood vessels [3]. Shi et al. 
[99] implicated VEGF in cell proliferation. It is therefore 
possible that the induction of VEGF by chronic hypoxia 
(which occurs far from the blood vessels and is associated 
with a high glucose uptake) is for cell proliferation and 
not for angiogenesis whereas acute hypoxia (which is 
found closer to stunted and/or blind blood vessels) induces 
VEGF for angiogenesis. 
VEGF’s role in tumor oxygenation via the 
vascularisation mechanism remains undisputed and needs 
to be considered in all assessments of tumor hypoxia. 
Glucose transporter 1 (GLUT-1) and tumor 
hypoxia
Cells primarily use glucose as an energy source 
which is converted to H2O and CO2 to produce ATP in 
the presence of oxygen (oxidative phosphorylation). In 
the absence of oxygen, glucose is converted to lactate 
(anaerobic glycolysis, Figure 4). Otto Warburg and his 
co-workers in 1920 demonstrated that compared to 
normal cells, tumor cells have a significant predilection 
for glucose metabolism under aerobic conditions, coined 
the Warburg effect [100, 101]. In his focus on glycolysis, 
Warburg demonstrated a reversed Pasteur effect by 
the inhibition of oxygen fermentation, implicating the 
glycolytic production of lactate even in the presence of 
sufficient oxygen, thus bypassing the entry of pyruvate 
into the citric acid cycle. The protons diffuse out of the cell 
into the extracellular environment to maintain intracellular 
homeostasis [100, 101]. 
Increased HIF-1alpha is associated with increased 
glucose consumption in a renal cell carcinoma cell 
line [102]. More glucose transporters are needed for 
more glucose uptake, so increased GLUT1, a glucose 
transporter, correlates with poor outcome for HNSCC 
patients, since it decreases apoptosis and therefore favors 
tumor growth [103, 104]. Grimm et al. [103] found that 
patients with increased GLUT1 and transketolase-like 
protein 1 (TKTL1) had a worse prognosis compared to 
patients with low GLUT1 and low TKTL1 levels. Mayer 
et al. [105] has questioned the antibody used for TKTL1 
detection and concluded that TKTL1 does not regulate 
glucose metabolism in malignant cells. Parallel to lactate 
production, tumor tissue is acidified, has increased 
invasiveness and eventually leads to metastasis [106]. 
The increase in lactate caused by the increased glycolysis 
could be used as a biomarker in measuring tumor hypoxia. 
Lactate and tumor hypoxia
It seems that any proliferating cell can use aerobic 
glycolysis [100] and that leukemia cells and lung cancer 
cells that are in direct contact with the bloodstream are 
highly glycolytic. Peppicelli et al. [107] hypothesized that 
increased hypoxia leads to increased glycolysis resulting 
in increased lactate and therefore increased acidosis which 
in turn compromises the surrounding cells and results in 
increased metastasis. This hypothesis was based on the 
investigations by Brizel et al. [108] and Ziebart et al. 
[109]. Ziebart et al. [109] took biopsies from 29 HNSCC 
patients with stage T3 or T4 tumors and from 9 control 
patients. They showed that lactate was increased and 
glucose was decreased in tumors compared to normal 
tissue. Walenta et al. [106] found that high tumor lactate 
levels, as measured by bioluminescence imaging, 
correlated to increased incidence of metastasis, tumor 
recurrence and a decreased overall survival. They found 
a positive correlation in the distribution patterns of ATP, 
glucose and lactate which is surprising considering that 
aerobic glycolysis is known to be an inefficient form of 
ATP production. Furthermore, lactate was not correlated to 
tumor hypoxia. Mariappan et al. [110] found a correlation 
between serum lactate levels and brain tumor grade. 
Unfortunately, no systemic condition of the patient was 
taken into account, especially since diabetic patients and 
chronic alcoholism have a higher basal serum lactate level 
than non-diabetic patients [111, 112]. No correlation was 
found between lactate levels and tumor staging [108, 109, 
113]. Lactate transporter monocarboxylate transporter 
4 (MCT-4) has to be induced by hypoxia and MCT-1 is 
needed to transport lactate in surrounding tumor cells. 
MCT-1 expressing cells show expression of KI-67 as 
well, indicating a higher replication.[114] HPV-positive 
cell lines appear to metabolise lactate more efficiently 
than HPV-negative cell lines [115]. Thus far, tumor lactate 
has been correlated with and seen as a reliable metabolic 
predictor for poorer prognosis and metastasis but the 
relationship between tumor hypoxia and lactate is still 
unclear [116].
Lactate Dehydrogenase (LDH) and tumor hypoxia
Lactate dehydrogenase catalyzes the reversible 
conversion of pyruvate to lactate. Lactate dehydrogenases 
are hetero or homo tetramers encoded by LDHA and 
LDHB genes. There are five isoenzymes: LDH1, 
LDH2, LDH3, LDH4 and LDH5. LDH5 expression 
independently correlates with poor prognosis and 
metastasis in HNSCC and is not expressed in normal 
head and neck mucosa [117]. Oropharyngeal tumors 
have higher LDH5 expression than other head and neck 
tumors. The serum LDH level in HNSCC patients is an 
independent prognostic factor and Hsieh et al. [118] and 
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Yao et al. [119] found that serum LDH above the upper 
limit of normal correlates with poor survival. LDH 
activity in saliva has also been correlated with periodontal 
disease [120]. LDH expression is significantly increased 
(88 %) in saliva from oral squamous cell cancer patients 
compared to age and sex-matched controls, independent of 
smoking, alcohol consumption and other diseases [121]. 
On the other hand an inverse correlation between tumor 
grade and LDH activity has been shown, furthermore 
HNSCC tumor cell lines xenografted into mice showed a 
correlation between LDH and pimonidazole staining [122, 
123]. Although increased serum LDH is mainly correlated 
with the incidence of cancer, its expression increases 
drastically during infection [124]. A link between both 
serum and tumor LDH and tumor hypoxia and prognosis 
is well established and should be included in future 
investigations. 
CA-IX (Carbonic Anhydrase IX) and tumor 
hypoxia
CA-IX comes from a family of zinc metalloenzymes 
that catalyze the reversible hydration of carbon dioxide. It 
is a transmembrane protein involved in various biological 
processes such as acid-base balance, the formation of 
saliva, cerebrospinal fluid and gastric acid and may be 
involved in cell proliferation. CA-IX is a prognostic 
marker for a number of malignancies [125]. In cervical 
cancer [126] and in HNSCC patients [25] there is no 
correlation between CA-IX staining and pO2 values. This 
is not supported by all research as Beasley et al. [127] 
confirmed the hypoxia dependent induction of CA-IX in 
three HNSCC cell lines. 
A meta-analysis including 16 studies and 1470 
patients showed that CA-IX is correlated with poor 
survival independent of tumor hypoxia [128]. The meta-
analysis did not take into consideration the different 
locations of the HNSCCs, only tumor size, tumor grade 
and nodal status. Brockton et al. [129] analysed 91 biopsy 
samples from HNSCC patients who had radio- and 
chemotherapy and found that CA-IX was not correlated 
to smoking status, gender, age, tumor site, tumor stage, 
performance status or response to therapy . They did, 
however, find a correlation between high stromal CA-IX 
levels and HPV p16-negative status and poor survival. In 
a cohort of 61 HNSCC patients with mainly HPV p16-
negative tumors, there was no correlation between CA-
IX and gender, age, tumor site, tumor stage, performance 
status or response to therapy but a correlation between 
CA-IX and smoking status and between high stromal CA-
IX and poor survival existed [130]. So, there seems to be 
prognostic relevance with a high stromal expression of 
CA-IX, however, our assessment may not be reliable or 
sensitive enough to verify its clinical relevance in tumor 
hypoxia. 
Osteopontin and tumor hypoxia
Osteopontin (OPN) is a phosphoglycoprotein that 
plays a role in bone remodeling, immune response and 
inflammation [131]. Le et al. [132] and Nordsmark et al. 
[25] were able to show an inverse relationship between 
plasma osteopontin and pO2 in HNC patients but no 
correlation between tumor osteopontin (obtained through 
immunohistochemical staining) and pO2 levels. A year 
earlier, Bache et al [133] found a correlation between 
osteopontin immunoreactivity, HIF-1alpha, Hb and VEGF 
but not with pO2 or CA-IX. They also found no correlation 
between HIF-1alpha, CA-IX and pO2. Overgaard et al. 
[134] used data from 320 patients from the Danish Head 
and Neck Cancer Group (DAHANCA) and found that 
high concentrations of plasma osteopontin predicted poor 
outcome but this could be attenuated when the patients 
were treated with nimorazole, a hypoxia radiosensitizer, 
during radiotherapy. Lim et al. [135] analysed data from 
578 HNSCC patients (Trans Tasman Radiation Oncology 
Group: TROG study) and found no correlation between 
OPN and poor survival nor did they find any effect with 
the tumor radiosensitizer tirapazamine. It is not clear 
why these results are so different to those found in the 
DAHANCA study, though the TROG study appeared to 
be more stringent in their analysis, and the blood samples 
used in the DAHANCA study had been stored for nearly 
19 years, while those used in the TROG study were fresh. 
Osteopontin secretion furthermore showed no correlation 
with hypoxia in 4 nasopharyngeal cancer cell lines [136]. 
Plasma osteopontin levels in metastatic nasopharyngeal 
carcinoma patients and HNSCC patients were elevated 
compared to controls and were a significant predictor of 
response to radiotherapy [136]. Tumor hypoxia increases 
metastasis and Courter et al. [131] found that osteopontin 
regulates tumor growth and metastasis by inhibiting 
apoptosis.
Low-grade inflammation as is evident in diabetes 
and metabolic syndrome has been associated with 
osteopontin derived from macrophages. Ahmad et al. 
[137] found a positive correlation between circulating 
osteopontin, fasting blood glucose and BMI. Smoking 
increases plasma osteopontin in type 2 diabetic patients 
[138]. The evidence correlating both serum and tumor 
osteopontin with tumor hypoxia and survival is mostly 
supportive, however some contradictory evidence 
mandates further research-
Nitric Oxide and tumor hypoxia
Nitric oxide is a free radical and an important 
signaling molecule involved in vasodilation and in 
protection against ischemic damage. Both salivary and 
serum nitric oxide can be used to determine oral mucosal 
disease, as well as oral precancer and cancer status in 
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patients [139-142]. NO is synthesized by nitric oxide 
synthase of which three isoforms are known, namely, 
inducible (iNOS), neuronal (nNOS) and endothelial 
(eNOS) nitric oxide synthase. It appears that the activity 
of VEGF may be upregulated by NO generation by eNOS 
and thus be implicated in tumor growth[98]. iNOS has 
also been shown to be a HIF target [143]. The role of NO 
in neovascularisation has already been discussed.
Despite significant complexities, current evidence 
supports NO as a prognostic marker and it has been 
shown to induce non-oxygen dependent HIF stimulation. 
Although increased NO is linked to poor outcome in 
cancer patients, NO has been shown to significantly 
increase cell apoptosis via p53 expression [144]. 
p53 and tumor hypoxia
p53 is a tumor suppressor protein encoded by the 
TP53 gene in humans. It is activated by a myriad of 
stressors, one of which is oxidative stress. In a mouse 
model DM2, a protein encoded by the DM2 gene inhibits 
p53 by transporting it from the nucleus to the cytosol or 
by attaching ubiquitin to p53 so that it can be degraded. 
Adduri et al. [145] found that p53 nuclear stabilization 
differed between ‘old’ and ‘young’ patients with squamous 
cell carcinoma of the tongue, being lower in ‘older’ 
Table 1: Inflammatory biomarkers related to head and neck tumors and tumor hypoxia  
Biomarker Material tested Method Result interpretation Reference
CD8 (Tumor 
Infiltrating 
Lymphocytes)
tumor *IHC High CD8+TIL (HPV positive tonsillar and base of tongue SCC) = better survival [181]
CD44 (Tumor 
Infiltrating 
Lymphocytes)
tumor IHC Low expression (HPV positive oropharyngeal SCC) = very high survival [182]
IDO (Indoleamine 
2,3-dioxygenase) tumor IHC
High tumoral (laryngeal SCC) expression 
= poor outcome (inhibited local 
immunity)
[183]
PD1 (programmed 
death 1) tumor IHC
High expression (HPVpos.HNSCC) 
= good prognosis. It can be efficiently 
blocked by anti-PD1 (melanoma, 
colorectal and renal cancer)
[184]
MIF (Macrophage 
Inhibitory Factor) tumor IHC
Increased expression of MIF in tumor 
cells & TILs predicts improved patient 
survival (nasopharyngeal carcinoma)
[185]
IL-15 (Interleukin) tumor IHC High intratumoral expression = poor clinical outcome (HNSCC) [186]
TGFβ1 
(Transforming 
growth factor β 1)  
tumor IHC Overexpression might predict oral cancer metastasis [187]
SMAD 6 & 7 
(regulators of TGFβ 
pathway)
tumor IHC Loss of expression = poor prognosis (HNSCC) [188]
CSF1R (Colony 
stimulating factor 1 
receptor) 
tumor IHC Up-regulated in radiation-resistant HNSCC [189]
MALT1 (Mucosa-
associated lymphoid 
tissue 1)
tumor IHC Loss of expression = poor prognosis (oral cancer) [190]
CXCR4, also known 
as SDF-1 tumor IHC
High expression = poor prognosis 
(tongue cancer) [191]
ArginaseII tumor IHC Absence of expression = prolonged overall survival (HNSCC) [192]
*IHC: Immunohistochemistry
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patients. Both p53 nuclear stabilization and p53 mutations 
were correlated with poor survival in the patients. 
Persistent expression of wild type p53 can be seen as a 
positive predictor for radiosensitivity [146]. This is in 
contrast to Portugal et al. [147] who found no correlation 
between p53 gene mutation and recurrence or survival 
status but who did, however, find a correlation between 
p53 gene mutation and alcohol use. The correlation of p53 
gene mutation and alcohol-use corroborated the results of 
Sorensen et al. [148] who found that non-smoking, non-
drinking young patients with squamous cell carcinoma of 
the tongue had less p53 mutations than their counterparts. 
As mentioned earlier, alcohol and cigarette use are 
independent prognostic factors for poor survival. 
Thus far it has been thought that inhibiting the 
MDM2/HIF-1alpha interaction would result in tumor cell 
death in hypoxia [149] but recently Joshi et al. [86] found 
that MDM2 causes HIF-1alpha to be degraded during 
hypoxia so inhibiting the MDM2/HIF-1alpha interaction 
may actually result in tumor growth, not death. The role of 
Table 2: Genetic biomarkers related to head and neck tumors and tumor hypoxia
Biomarker Material tested Method Result interpretation Reference
PTEN (Phosphatase 
and Tensin homolog) tumor *IHC
High expression in HNSCC = 
significant gain in loco-regional control [193]
mTOR (mechanistic 
Target of Rapamycin) tumor IHC
High expression = shorter DFS 
(laryngeal cancer) [194]
PK-M2 & PK-M1 
(Pyruvate kinase 
isozymes M1/M2)
tumor IHC Isoform switch to higher expression of PK-M2 = poor prognosis (HNSCC) [195]
integrin αvβ5 tumor IHC High expression = high risk of metastasis (Laryngeal SCC) [196]
PDK-1 (Pyruvate 
dehydrogenase 
kinase-1)
tumor IHC High expression = poor prognosis (HNSCC) [197]
Ki-67 tumor IHC High expression = good prognosis (Oral SCC) [198]
p27 tumor IHC
High expression = good response 
of HNSCC to chemotherapy 
(Cisplatin+5FU)
[199]
EGFR (epidermal 
growth factor receptor) tumor IHC
High expression predicts better 
loco-reg. control of HNSCC with 
Contin. Hyperfract. Acceler. Radioth. 
(CHART)
[200]
LOX (Lysyl oxidase) tumor IHC High expression = poor overall survival (HNSCC) [201]
*DSPP, OPN, MMP-9 tumor IHC Expression in negative tumor margins predict recurrence of oral cancer [202]
MMP-13 (Matrix 
metalloproteinase-13) tumor IHC
high nuclear MMP-13 expression = 
poor outcome (tongue cancer) [203]
CytK13, CytK 
14 and CytK 16 
(Cytokeratins)
tumor IHC
Loss or downregulation = poor 
prognosis (recurrence & metastasis of 
tongue cancer)
[204]
CytK19 (Cytokeratin 
19) tumor IHC
Decreased in tumor: metastasis 
(HNSCC) [205]
Slug (necessary for 
HIF-1α induced 
cadherin switch)
tumor IHC High expression = tumor invasion and short survival (HNSCC) [206]
HDAC2 & pVHL 
(Histone deacetylase 2 
& von Hippel–Lindau 
protein)
tumor IHC
High HDAC2 & low VHL expression 
= advanced stage and poor prognosis 
(Oral SCC)
[207, 208]
CTGF (Connective 
Tissue Growth Factor) tumor IHC
High expression = poor prognosis 
(HNSCC) [209]
Galectin 1 and 3 tumor IHC High expression correlates with tongue SCC metastasis [210]
* IHC: Immunohistochemistry; DSPP: dentinsialophosphoprotein; OPN: osteopontin; MMP-9: matrix 
metalloproteinase-9 [70]
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p53 and its mutations can be regarded as well established 
in HNSCC, however its precise interrelationship with 
tumor hypoxia needs to be explored and clarified further. 
Genetic regulation and interplay in cancer is 
demonstrated by the extensive research on microRNAs.
MicroRNAs and tumor hypoxia
MicroRNA (miRNAs) are short noncoding RNAs 
that posttranscriptionally regulate target messenger RNAs 
[150]. 7 microRNAs are consistently upregulated in 
HNSCC, namely, miR-21, miR-7, miR-155, miR-130b, 
miR-223, miR-34b, miR-210 and 4 are consistently 
downregulated, namely, miR-100, miR-99a, miR-125b, 
and miR-375 [151]. We will mainly take a closer look at 
miR-21, miR-210 and miR-375.
miR-21 which is the most researched miRNA, is 
upregulated in various cancers [152]. It is anti-apoptotic 
and is expressed in the tumor stroma of HNSCC tumors 
[150]. Gee et al. [15] could find no correlation between 
miR-21 and other markers for tumor hypoxia in HNSCC 
patients. In vitro, Polytarchou et al. [153] found that 
Akt2 promotes hypoxia resistance via upregulated miR-
21 whereas Loayza-Puch [154] found that hypoxia 
downregulates RECK (a tumor-suppressor protein) via 
upregulated miR-21. 
miR-210 is consistently induced by hypoxia as a HIF 
target in normal and transformed cells [155]. It correlates 
with markers of tumor hypoxia in HNSCC patients, such 
as HIF-1alpha, CA-IX and a 99-gene hypoxia metagene 
[15]. To our knowledge, miR-210 is only regulated by 
hypoxia.
miR-375 is downregulated in HNSCC alluding to it 
being a tumor suppressor. Possible target genes of miR-
375 are those involved in cell growth and insulin secretion 
[156]. Congruent with its effect on insulin secretion, high 
levels of miR-375 correlate with the incidence of diabetes 
and miR-375 has been suggested as a biomarker for not 
only cancer [157, 158]but Type 2 diabetes as well [159]. 
Overexpressing miR-375 in vitro in laryngeal cancer 
cell lines (SNU-48 and SNU-899) resulted in increased 
apoptosis and decreased proliferation and invasivity 
[160] which fits with the evidence that miR-375 acts via 
phosphoinositide-dependent protein kinase-1 [161]. miR-
375 correlates to tumor staging and tumor size but no 
experiments were done regarding tumor hypoxia directly 
[162].
Although miRNAs look promising as biomarkers 
for HNSCC, they are regulated by various cancers and 
diseases and their role in tumor hypoxia needs further 
elucidation. Table 1 and Table 2 depict a further list of 
possible inflammatory and genetic biomarkers relevant to 
HNC as found in the current literature.
Genetic profiling
Various efforts have been made to define and utilize 
genetic head and neck tumor profiling. A number of 
gene expression subtypes can be identified nanely basal 
(31%), mesenchymal (27%), atypical (24%) and classical 
(18%). Some promising findings have been forthcoming 
and further research is needed to elucidate their potential 
clinical relevance. 
For example, it was shown that the NFE2L2 
oxidative stress pathway is a tobacco-related signature not 
specific to an anatomic tumor site. HPV-positive tumors 
show recurrent deletions and mutations of TNF receptor 
associated factor 3 gene loss as well as mutations in exon 
9 of the PIK3CA helicase domain. Tumor cause can now 
thus be confirmed genetically [60]. A 26 gene hypoxia 
signature has been used used to calculate a hypoxia 
score to predict treatment benefit for a hypoxia adapted 
treatment with carbogen and nicotinamide protocol 
before radiotherapy in 157 larynx cancer patients. High 
expression of hypoxia related genes did predict for a 
poorer 5 year survival however not for the value of 
hypoxia modification treatment [163]. In an attempt so 
simplify further, clinically relevant research, smaller, more 
robust signatures or metagenes have been developed[164, 
165]. 
Tourstup K et al.[157, 158]developed a 15 gene 
hypoxia classifier with prognostic impact that was 
verified it in the DAHANCA 5 study cohort and is now 
being implemented in a prospective accelerated chemo-
radiotherapy trial with or without the radiosensitizer 
nimorazole in HPV negative HNSCC patients (EORTC 
1219). 
Imaging
Imaging may be a possible alternative to profiling 
tumor hypoxia. [F-18] fluoromisoni-dazole (FMISO), 
(18)F-fluoroazomycin arabinoside (FAZA)-PET, dynamic 
contrast enhanced MRI , arterial spin labelling (ASL) MRI 
and other MRI techniques have all shown promise in this 
regard, and may allow hypoxic tumors to be defined in a 
non- invasive and possibly continuous manner. Imaging 
may even allow us to monitor treatment response [166-
170]. Near infra-red spectrometry may be a solution to 
predict oxygen content in more superficial tumors[171]. 
The major drawback of imaging thus far has been the 
lack of research proven correlation of the imaging to the 
various hypoxia parameters.
DISCUSSION
HNC comprises many different cancers in terms of 
aetiology, localization, duration, size, metastatic potential 
etc., yet in many analyses these diverse malignancies 
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are often grouped together that could lead to erroneous 
conclusions. It may therefore be more prudent to deal 
with each cancer separately and define the mechanisms 
and treatment separately, then again this further subtyping 
will further much needed diminish statistical power [91, 
172-174]. As a common denominator all these cancers are 
linked by tumor hypoxia as a prognostic factor, however 
the molecular pathways involved may be different and 
therefore treatments need to be more individualized. As 
described tumor hypoxia is only universal in terminology, 
but extremely diverse in term of definition as the 
measuring parameters range from physical measurement 
to various up and downstream metabolic products.
HIF-1alpha, CA-IX and Glut1 are used as the main 
markers to represent tumor hypoxia, but they fall short 
of the criteria for a true endogenous marker as listed by 
Janssen et al. [3]. These markers can, however, potentially 
be used to predict disease progression or overall survival, 
but independently of hypoxia as especially HIF is also 
influenced by non hypoxic driven factors. Imaging 
techniques such as FMISO, FAZA-PET and various MRI 
techniques such as arterial spin labeling, BOLD-MRI and 
quantitative diffusion MRI will probably lead the way to 
non invasive hypoxia measurements, but the metabolic 
interpretation will have to be validated with the various 
biomarkers as discussed [169, 175-177].
HPV, with HPV E7 being a known HIF-1alpha 
protein interactor [54], is becoming one of the main risk 
factors for HNSCC. Specifically oropharyngeal cancer 
with smoking acting as an compounding risk factor with 
the risk of death increasing steadily with every additional 
packyear [178]. Even though HPV-infected cancers are 
aggressive and grow rapidly, prognosis is generally good 
whereas tumor hypoxia in both HPV-positive and negative 
tumors results in poorer prognosis [179]. Does the answer 
to the differences in outcome lie in individualised immune 
response? Inflammation is known to play a role in tumor 
hypoxia but the role of inflammation in HPV-positive 
cancer is still unclear. Can the differences be attributed to 
the difference in the miRNA profile as suggested by Lajer 
et al. [180]?
There is no real standardization between clinical 
trials in terms of parameters set, e.g. the hemoglobin 
cut-off to determine anemia varies, pO2 as parameter for 
hypoxia varies and the term tumor hypoxia is erroneously 
used as a collective term for what should be called tumor 
oxygenation. It is therefore, surely not sufficient to look at 
a single marker for hypoxia but rather one probably needs 
several as shown by Hsieh et al. [118].
Despite the above outlined limitations in some of 
the understandings of tumor hypoxia, there are centres 
implementing adapted radiation protocols as standard of 
care.[24, 25] 
 As genetic profiling develops, the intricacies of the 
complex tumor hypoxia drama may be unraveled further, 
however it may also deepen the plot with hundreds of new 
key suspects arising, each playing a supporting role to 
the main role player, oxygen. Despite the ever expanding 
complex plot, there have been some positive discoveries 
with potential therapeutic relevance, like HIF-1alpha. 
This will pave the way for more individualized treatment, 
however, much more needs to be uncovered to be able to 
routinely follow and adapt treatment response.
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